Cancer patients, pharmaceutical companies, and clinical trial contract research organizations (CROs).

The Center for Precision Medicine of Chi Mei Hospital integrates expertise in pathology and precision medicine to establish a service platform covering the entire process from cancer genetic testing consultation clinics to testing and result interpretation. It also builds a comprehensive ecosystem encompassing assay development, validation, collaboration in clinical trials, and the real-world implementation. The genetic testing consultation clinic is led by pathologists with expertise in pathological diagnosis, targeted therapies, genetic testing, and cancer genetics, providing a complete workflow that includes test explanation, pathology review, specimen assessment, report issuance, and interpretation of genetic reports.Through various molecular testing technologies, the team maximizes specimen usability, overcomes multiple barriers faced by cancer patients in accessing genetic testing, and comprehensively enhances the accessibility, usability, and clinical utilities of genetic testing. The core laboratory also collaborates with pharmaceutical companies and CROs to hasten the translation from assay development to clinical application and to comprehensively optimize patient enrollment in cancer clinical trials.

• R&D capabilities which can be well integrated with early-phase clinical trials and establish a comprehensive ecosystem spanning assay development, validation, collaboration in case screening and real-world implementation of testing.

• A multidisciplinary team that emphasizes knowledge, technology, quality, and communication, ensuring professional and comprehensive cancer molecular diagnostic services.

• Tailoring optimized testing workflows and assays for different cancer types and specimen conditions, making the test possible in each patient specimen.

• By integrating the above strengths, establish a cancer genetic testing consultation clinic that delivers comprehensive services ranging from test explanation, pathology review, specimen assessment, and report issuance to genetic report interpretation.

• More than 2,000 cases of advanced non–small cell lung cancers are tested annually (about one-quarter of the cases in Taiwan).

• A unique cancer genetic counseling clinic, providing services to a cumulative total of 1,920 patient visits over 3.5 years.

• Fundraising-supported testing for lung cancer (between 2023–2025), supporting a total of 2,139 non–small cell lung cancer patients.

• The success rate of matching patients to National Health Insurance–reimbursed medications through the cancer genetic counseling clinic was 50.7% , including 61.3% (750 cases) for lung cancer and 42.4% (110 cases) for ovarian cancer.

• The genetic testing success rate for advanced non–small cell lung cancer was 99%.

• On average, more than 10 genetic testings (co)developed and certificated annually.

By using various and intergrated molecular testing technologies, the team achieves a high testing successful rate at 99% using lung cancer biopsy samples. 2. The overall success rate of matching patients to National Health Insurance–reimbursed medications was 50.7%.

• The continued referral rate from external physicians reached 97.7%.

• Customer satisfaction from external clients reached 95%.

• Textbook authorship in the IASLC molecular Atlas.

• Research findings cited in textbooks including the WHO Blue Book on tumor classifications.

• Invited by AstraZenec to draft international guidelines on genetic counseling for breast cancer.

• Participated in the development of Asian Consensus Guidelines for the Diagnosis and Management of

• Gastrointestinal Stromal Tumor.

• Proposed real-world lung cancer testing strategy recommendations for Taiwan, published in the Journal of Clinical Oncology Global Oncology (JCOGO).

• Signed a training agreement with the Vietnam Society of Pathology and Cytology to support molecular pathology training and local laboratory capacity building.

• Quality Enhancement: Achieved a 99% testing success rate with a industry-leading turnaround time. We received ISO 15189 certification to ensure diagnostic accuracy.

• Standards Development: Contributed to the book chapters and national/international guidelines of molecular diagnostic.

• Care Impact: Over 50% of patients benefited from optimized treatment strategies; access to care improved through our fundraising-supported testing public testing programs.

• Sustainable Development: Pioneered advocacy for NGS reimbursement under national health insurance; supported global medicine by training overseas physicians.